EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Imatinib is effective in some PDGFRA/B ‐negative hypereosinophilic syndromes: A step closer to unveiling underlying mechanisms

Giuseppe G Loscocco iD, Grzegorz Helbig iD

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19853 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Giuseppe G Loscocco und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Unive…. Hauptthemen laut MEDLINE: Hypereosinophilic Syndrome, Imatinib Mesylate, Receptor, Platelet-Derived Growth Factor alpha. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypereosinophilic syndromes (HES) comprise different clonal, reactive, or idiopathic disorders characterized by elevated eosinophil levels and subsequent organ damage. Kim et al. in a multicentre, single‐arm, prospective phase II study, treated 32 patients with PDGFRA/B ‐negative HES with imatinib at the dose of 100–400 mg daily. Respective overall and complete haematological response rates were 46.9% and 18.8%, and the median time to response was 1.5 months. The molecular basis of responses was identified by using whole‐exome and whole‐transcriptome sequencing in 11 patients. STAT5B::RARA , PAK2::PIGX , and FIP1L1::CHIC2 fusions were identified in responders, whereas RNF130::BRAF and WNK1::KDM5A were identified in non‐responders. Imatinib could be a therapeutic option for some, possibly clonal, PDGFRA/B ‐negative HES. Commentary on: Kim et al. Phase II trial of imatinib mesylate in patients with PDGFRA/B ‐negative hypereosinophilic syndrome. Br J Haematol 2024; 205: 2305‐2314 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypereosinophilic SyndromeImatinib MesylateReceptor, Platelet-Derived Growth Factor alphaHumansReceptor, Platelet-Derived Growth Factor betaMale

Stichwörter der Autor:innen

PDGFRAPDGFRBeosinophiliahypereosinophilic syndromeimatinib

Substanzen

Imatinib MesylateReceptor, Platelet-Derived Growth Factor alphaReceptor, Platelet-Derived Growth Factor betaPDGFRB protein, human

Autor:innen und Institutionen

  • Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
  • Department of Hematology and Bone Marrow Transplantation, Faculty of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.

ORCID-Profile: Giuseppe G Loscocco, Grzegorz Helbig

Zitieren

APA

Loscocco, G. G., & Helbig, G. (2024). Imatinib is effective in some PDGFRA/B ‐negative hypereosinophilic syndromes: A step closer to unveiling underlying mechanisms. British Journal of Haematology. https://doi.org/10.1111/bjh.19853

Vancouver

Loscocco GG, Helbig G. Imatinib is effective in some PDGFRA/B ‐negative hypereosinophilic syndromes: A step closer to unveiling underlying mechanisms. British Journal of Haematology. 2024. doi:10.1111/bjh.19853

BibTeX
@article{Loscocco2024,
  author = {Loscocco, Giuseppe G and Helbig, Grzegorz},
  title = {Imatinib is effective in some PDGFRA/B ‐negative hypereosinophilic syndromes: A step closer to unveiling underlying mechanisms},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19853}
}
Kostenlos starten →